{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-021953","form_type":"8-K","ticker":"TYRA","cik":"0001863127","company_name":"Tyra Biosciences, Inc.","filed_at":"2024-02-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.134019+00:00","generated_at":"2026-06-06T11:35:33.100282+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"FDA grants Rare Pediatric Disease Designation to Tyra Biosciences' TYRA-300 for achondroplasia","bullets":["FDA granted Rare Pediatric Disease Designation to TYRA-300, an oral FGFR3 inhibitor, for achondroplasia.","If NDA approved, Tyra may receive a Priority Review Voucher (PRV) that can be sold or transferred.","Company plans to submit IND in H2 2024 for a randomized Phase 2 trial in children with achondroplasia.","RPD Designation is for diseases affecting <200,000 in US and primarily individuals under 18 years."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-021953","json":"https://secwatch.observer/filing/0001193125-24-021953.json","markdown":"https://secwatch.observer/filing/0001193125-24-021953.md","text":"https://secwatch.observer/filing/0001193125-24-021953.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1863127/000119312524021953/0001193125-24-021953-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1863127/000119312524021953/d674967d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T11:35:33.100282+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}